Filing Flows › Jazz Pharmaceuticals (JAZZ) › R&D spending
Jazz Pharmaceuticals (JAZZ) R&D spending by quarter
Jazz Pharmaceuticals' R&D spending was $212M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $181M (Q1 2025) to $214M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $212M | +2% | +7% |
| Q2 2026 | $208M | +6% | +9% |
| Q1 2026 | $196M | -8% | +8% |
| Q4 2025 | $214M | +8% | — |
| Q3 2025 | $198M | +4% | — |
| Q2 2025 | $190M | +5% | — |
| Q1 2025 | $181M | — | — |
Q3 2026 at a glance
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
What is Jazz Pharmaceuticals' R&D spending?
Jazz Pharmaceuticals' R&D spending was $212M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Jazz Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $181M (Q1 2025) to $214M (Q4 2025).